AVGO
$322.23 at the check
SHORT

Kairon's answer on AVGO: leaning down.

Leaning down, but not enough conviction for a trade.

Checked Nov 3, 2026 at $322.23, time frame 2-6 weeks, confidence high
Why? For, against, what would change it
  • ForAVGO nearly doubled revenue and earnings per share over the past year, with operating margin of 54.3% and net margin of 42.9%.
  • AgainstShares outstanding increased 1056% in 3 years, causing extreme dilution that threatens per-share value even with current profit growth.
  • What would change the pictureIf EPS growth drops below 10% YoY or if price falls below $305 and does not reverse, the outlook would worsen.
Result check on Dec 15, 2026: open.

The 10-second check

Loading filings…

Both sides

More for

AVGO is achieving industry-leading growth and profitability, as measured by nearly doubling revenue and earnings per share in the past year and maintaining exceptionally high margins.

Despite elevated trailing PE, AVGO’s forward valuation is reasonable, and its PEG ratio of 0.32 signals that future growth is not only strong but undervalued relative to the price.

More against

Extreme dilution has materially destroyed per-share value.

Elevated trailing PE and price/book ratios leave AVGO vulnerable to multiple compression, especially if growth slows or fails to offset dilution risk.

Read the full debate between the bull and the bear analyst

Bull Analyst: BULL CASE ARGUMENTS

---

Argument 1 – Category: Growth & Profitability | Conviction: HIGH
Evidence: Revenue growth +93.8% YoY; EPS growth +96.8% YoY; Operating margin 54.3%; Net margin 42.9%; ROE 44.2%
Thesis: AVGO is achieving industry-leading growth and profitability, as measured by nearly doubling revenue and earnings per share in the past year and maintaining exceptionally high margins (operating >54%, net >42%). This is supported by robust return on equity (44.2%), demonstrating both effective scaling and disciplined capital management. Fundamental Score 7.2/10 (top decile of composite models) further affirms underlying corporate performance.

---

Argument 2 – Category: Valuation Relative to Growth | Conviction: HIGH
Evidence: Forward PE 16.55; PEG Ratio 0.32
Thesis: Despite elevated trailing PE (41.15), AVGO’s forward valuation is reasonable (PE 16.6), and its PEG ratio of 0.32 signals that future growth is not only strong but undervalued relative to the price. This suggests rapid normalization of valuation as earnings scale, mitigating claims of premium valuation based only on trailing metrics.

---

Argument 3 – Category: Cash Flow & Quality | Conviction: MEDIUM
Evidence: Free Cash Flow $30.6B (TTM); Current ratio 2.5
Thesis: AVGO’s substantial free cash flow ($30.6B TTM) and strong liquidity (current ratio 2.5) provide resilience against market downturns, fund strategic investments, and hedge against risks from dilution and elevated leverage, supporting earnings quality (score 7/10).

---

Argument 4 – Category: Technical/Mean Reversion Setup | Conviction: MEDIUM
Evidence: RSI 39.3 (oversold); Price at lower Bollinger band ($309.99); Mean-reversion signals: Williams %R +83, Days since 52w low +81, MC expected return +4.18%, P(up) 60.7%
Thesis: While momentum and trend signals are weak, AVGO is oversold and mean-reversion signals are strong, with MC simulation showing a 60.7% probability of positive 21-day return and expected +4% bounce. The technical setup at the lower Bollinger band with high downside volume suggests potential for tactical rebound, though risk is elevated.

---

BEAR COUNTER-ARGUMENTS

---

Bear said: "Shares outstanding up 1056% in 3y (massive dilution, highly destructive for per-share value)."
Counter: While dilution is severe (shares up from 412.74M to 4.77B), AVGO’s EPS grew +96.8% YoY and revenue +93.8% YoY, meaning internal growth (profitability/margin expansion) has offset much of the per-share value destruction so far. Forward EPS estimates remain robust ($19.47) and FCF is strong ($30.6B TTM), indicating the dilution effect has been partially neutralized in operational terms, though it is a legitimate risk.

---

Bear said: "Wide analyst price target dispersion; low consensus/confidence."
Counter: Target mean $530.1 (+64.5% upside), median $537.5 (dispersion 83.8%), showing significant analyst upside expectations. While dispersion points to lack of consensus, the directionality (majority targets >50% higher) signals analysts see material value uplift, even if conviction is low.

---

Bear said: "Estimate trends are flat-to-slightly downward for annual EPS, not strong upward."
Counter: Quarterly estimate revisions are on a weak upward trend (latest surprise % beats: 4.38%, 1.32%, 1.74%, 2.53%), showing PEAD positive and four consecutive earnings beats. This supports a thesis for continued operational outperformance even as annual forecasts flatten.

---

Bear said: "Price/Book 15.43, PE TTM 41.15; premium, not supported by peer data."
Counter: Forward PE is 16.55, PEG is 0.32, and rapid EPS/revenue growth means premium valuation compresses quickly. PEG below 1 is rare and attractive in growth names; while peer comparison is unavailable, AVGO’s self-consistent metrics indicate valuation normalizes as profitability scales.

---

Bear said: "AVGO is much weaker than market/peers (technical, relative strength low)."
Counter: Quant regime is mean-reverting (Hurst 0.43), MC up probability 60.7%; mean-reversion and oversold conditions suggest structural weakness may be offset by statistical bounce potential (expected +4% return, 21-day window) with high realized volatility, supporting tactical long setups despite poor momentum.

---

BULL THESIS INVALIDATION LEVEL

The bull thesis breaks if:
- EPS growth falls below 10% YoY (next earnings), indicating dilution impact is no longer offset by performance.
- Price closes below $305 (major support, prior range lows, setup break) and fails to base/reverse.
- Forward PE rises above 25 with no corresponding upward revision in earnings, indicating deteriorating growth/valuation normalization.

---

OVERALL BULL CONVICTION: MEDIUM (6/10)
Justify:
- Two HIGH conviction arguments (growth/profitability and valuation relative to growth), both with robust and specific metrics.
- Other points are MEDIUM due to technical weakness and risk from dilution.
- Mean-reversion setup raises tactical opportunity, but regime alignment and quant signals are mixed, and dilution remains a legitimate risk whose impact must be monitored.
- Upside hauls outweigh downside only if operational excellence persists and technical bounce occurs; otherwise, dilution and weak trend invalidate the bull thesis.
Bear Analyst: ## BEAR CASE RISKS

---

Risk 1 – Category: Dilution / Per-Share Value Destruction | HIGH conviction
Evidence: Shares outstanding up 1056% in 3 years (from 412.74M to 4.77B).
Risk: Extreme dilution has materially destroyed per-share value. Even with EPS growth +96.8% YoY, dilution outpaces growth on a multi-year basis. If dilution continues or if profitability slows, per-share value will decline further.
Quantified downside: If AVGO reverts to pre-dilution per-share value (all else equal), stock could decline up to 40–55% from current levels (based on historic dilution and similar tech capital raising events).

---

Risk 2 – Category: Valuation (Premium / Compression) | MEDIUM conviction
Evidence: TTM PE: 41.15; Price/Book: 15.43; Forward PE: 16.55; PEG: 0.32. No sector peer data to justify the valuation premium.
Risk: Elevated trailing PE and price/book ratios leave AVGO vulnerable to multiple compression, especially if growth slows or fails to offset dilution risk. Without peer data confirming sector justification, valuation may be at risk.
Quantified downside: If forward PE compresses from 16.55 to 12 (growth scares/sector re-rate, using historical tech bear cycles), downside = 27.5%.

---

Risk 3 – Category: Technical / Relative Weakness | HIGH conviction
Evidence: Price is 12.1% below 200SMA ($366.54 vs $322.23), RSI at 39.3 (weak), Quant composite -20.2/100, current drawdown -32.86%.
Risk: AVGO is a structural laggard in a bull market (SPY +3.6% over 200MA); if the market turns, AVGO likely underperforms. With momentum and trend signals deeply negative, technical breakdown may accelerate.
Quantified downside: If AVGO retests 1-year drawdown low ($305), downside from current price = 5.3%. If it breaches $300 (major support), next stop is $267 (historical range)—17% downside.

---

Risk 4 – Category: Estimate Trends / Forecast Risk | MEDIUM conviction
Evidence: Annual EPS estimate flat/slightly downward (FY EPS: 19.47 vs 90d ago: 19.58). Analyst price target dispersion is extremely wide: 83.8%.
Risk: Earnings growth has lost momentum; four quarterly beats mask a flat annual revision. Analyst consensus is weak (mean $530.1, high $660, low $215.9); with wide dispersion, low conviction. Flat estimates + wide dispersion = risk of negative revision.
Quantified downside: If next annual EPS guide falls < $15, forward PE rises > 20, implying 20–25% downside on growth re-rate.

---

Risk 5 – Category: Balance Sheet & Leverage | LOW conviction
Evidence: Debt/Equity at 59.6 (moderately elevated); Current Ratio strong (2.5).
Risk: Debt is material but not extreme. If leverage increases or FCF declines, rating agencies may penalize; not an immediate stressor given large free cash flow.
Quantified downside: If Debt/Equity jumps to >80, could cause 10% downside from forced selling/credit concerns.

---

## BULL COUNTER-ARGUMENTS

---

Bull said: "AVGO is achieving industry-leading growth and profitability (Revenue +93.8% YoY, EPS +96.8% YoY, margins >54%, ROE 44.2%)."
Counter: Dilution of 1056% outpaces both revenue and EPS growth. Three-year EPS CAGR cannot offset magnitude of dilution without continued >90% YoY growth—unlikely sustainability. High margins may compress if dilution-driven capital event was needed for operational scale; prior history of 4.77B shares (up from 412M) suggests internal growth likely cannot offset dilution over time.

---

Bull said: "Forward PE 16.55 and PEG 0.32 indicate strong growth relative to price."
Counter: Forward PE assumes flat-to-increasing EPS; annual estimate trend is weak (FY EPS: 19.47 vs 90d ago: 19.58, marginally downward). PEG of 0.32 is attractive only as long as growth persists; quant/analyst signals (price target dispersion 83.8%) reflect low confidence in maintaining such growth. Trailing PE (41.15) remains risky if any forward miss occurs.

---

Bull said: "Substantial FCF ($30.6B TTM), liquidity (current ratio 2.5) = resilience."
Counter: Free cash flow is strong, but if the massive capital raise (dilution) was used to bolster FCF or finance acquisitions, quality of FCF and margin maintenance may be at risk in coming quarters. Debt/Equity 59.6 is elevated versus tech norms; required capital may be masking underlying earnings weakness.

---

Bull said: "Mean-reversion signals (RSI 39.3, Williams %R +83, MC up probability 60.7%) = tactical rebound odds."
Counter: Quant/technical scores overwhelmingly bearish: Trend score 2/10, Momentum score 2/10, Relative Strength score 2/10, Composite quant -20.2/100, current drawdown -32.86%. Mean-reversion regime only offers low-conviction tactical bounces; structural weakness is dominant and may overwhelm short-term signals.

---

## RED FLAGS FROM ANALYST REPORTS

- Shares outstanding up 1056% in 3 years: Massive dilution—unprecedented for large cap, indicates destructive capital event.
- Price/Book 15.43: High premium, not peer justified.
- Analyst price targets dispersion 83.8%: Extremely wide, consensus low.
- Current drawdown -32.86%: Near 1-year extreme.
- Insider selling ($250M in past 90 days): No buys, one large sale.
- Estimate trend: FY EPS marginally downward vs 90d ago.

---

## BEAR THESIS CONFIRMATION SIGNAL

The bear thesis accelerates if:
- Price closes and holds below $305 (major support, prior range lows)—technical breakdown.
- Shares outstanding continue to rise above 4.77B next quarter.
- Annual EPS estimate revises downward (>5%) or falls below $15.
- Debt/Equity rises above 80 (would indicate leverage stress).
- Insider selling continues at >$250M per quarter.

---

## OVERALL BEAR CONVICTION: HIGH (9/10)

Justify:
- Two HIGH conviction risks (massive dilution; technical/relative weakness), both with multi-source, quantified evidence.
- Several major red flags: dilution unprecedented, technicals heavily negative, analyst confidence low, momentum structurally weak, and estimates flat-to-downward.
- Market is in bull regime, but AVGO is a laggard and would be hit hardest in a downturn.
- Tactical mean-reversion bounce is a valid argument, but bears dominate on multi-quarter and multi-factor signals.
- Downside risk is quantifiable and substantial if any fundamental or technical breakdown occurs.
Conclusion: AVGO faces severe dilution risk, structural technical weakness, and valuation compression factors, making it a high conviction short or underweight unless clear reversal signals emerge.

Want a fresh check?

A new AI check reads today's prices, news and filings. Compact check: one per month free with an account, ready in a few minutes. Full check with every analyst and chart technicals: in a plan or €3.99 once, about 10 minutes.

Start a new AI checkCheck your own entry (free)

Kairon's record on AVGO

2 past checks: 1 directional calls (1 right, 0 wrong), 1 × wait (afterwards −15.6 % on average). Measured by price since each check, no costs. How we measure. Every 'not now' answer.

Nov 3, 2026: Short at $322.23, −5.5 % sinceright
Jul 3, 2026: Wait at $360.45, anyone who bought anyway: −15.6 %wait

Insider and Congress filings

Loading…

Official SEC Form 4 and House PTR filings. Returns run from the first close after a filing became public. A filing is a fact, not a recommendation.

Full report (technical terms)

Key levels

Support$310.00
Resistance$335.00
Horizon2-6 weeks
Quant score-20/100

Executive summary

No long trade is justified in AVGO as of 2026-11-02. Reward/risk is 0.74:1, well below the fund's 2:1 minimum. Technical conviction is extremely low (2.7/10), mean-reversion signals are not supported by price structure, and expected value is negative. AVGO remains a structural laggard with elevated risk and ongoing dilution; wait for a technical base and better R/R before reconsidering.

Investment thesis

All three risk managers independently call PASS. Technical setup is weak: AVGO trends and momentum are deeply negative, well below key moving averages, with major dilution undermining fundamental positives. Both momentum and mean-reversion signals are conflicted, leading to very low conviction (2.7/10 technical, 7.2/10 fundamental, but technical governs entry). R/R is 0.74:1 and EV is negative (–2.84%), violating fund minimums. Past performance lessons confirm that entries against trend and with weak technical structure are consistently unprofitable. NO_TRADE is a strict requirement by all framework triggers.

Valuation assessment

Despite healthy top-level financials, per-share value is structurally compromised by massive dilution. AVGO trades well below its 200SMA (–12%) and sector/market peers, with a –1.07 Sharpe, deep drawdown (–32%), and weak technicals. Analyst price targets are highly dispersed, which has historically predicted poor returns for this setup. Market assigns wide probability bands and negative edge: valuation does not justify a long swing entry here.

Scenario analysis

Bull case: Oversold bounce to $335 (25%) or $350 (10%), only if reversal base forms—currently no evidence supports this. Base case (35%): AVGO remains a laggard, trades range-bound or drifts down to $310; if $310 breaks, downside extends to $300 (10%). Immediate technical odds strongly favor continued underperformance unless a base/reversal is confirmed. Mean-reversion signals argue for bounce potential, but history and trend alignment lessons support waiting for confirmed technical improvement.

Key risks

Key technical, structural, and liquidity/tail risks: 1) Momentum and trend are negative; 2) Ongoing massive share dilution (~1056%) is a long-term headwind even with strong fundamentals; 3) Downside tail to $300 not unlikely in further market/sector weakness. No show-stoppers on event risk, but no positive edge here.

AI-generated. Created 2026-11-03 13:02 UTC automatically by Kairon AI (Cem Salomon Weidner, Vienna, Austria) at a price of $322.23. Valid for its time frame from that moment; it is not updated afterwards. Facts come from public sources (Yahoo Finance and others, partly delayed); the rating, levels and scenarios are opinions of the AI. General information, not investment advice and not a solicitation to buy or sell. Conflicts of interest, methodology and risks: disclosure. Every past call and its outcome: track record.

Open this analysis in the app

More checks

Learn the method

Kairon AI is an automated research and second-opinion tool, not a licensed financial advisor, broker, or investment manager. All assessments are AI-generated opinions based on public data and are informational only — not personal investment advice. Investing carries risk, including total loss of capital.

Impressum Privacy Terms Disclaimer